Effects of granulocyte macrophage colony-stimulating factor, nerve growth factor and interleukin-17 on autoimmune prostatitis
10.3969/j.issn.1009-8291.2023.10.015
- VernacularTitle:粒细胞巨噬细胞集落刺激因子、神经生长因子、白介素-17在自身免疫性前列腺炎中的作用
- Author:
Shicheng FAN
1
;
Yuanquan ZHU
1
;
Shengbin LI
1
;
Yongbo CHU
1
;
Qingpeng CUI
1
Author Information
1. Department of Urology, The Third People’s Hospital of Yunnan Province, Kunming 650032, China
- Publication Type:Journal Article
- Keywords:
chronic prostatitis/chronic prostatitis;
granulocyte macrophage colony-stimulating factor;
nerve growth factor;
interleukin-17
- From:
Journal of Modern Urology
2023;28(10):894-899
- CountryChina
- Language:Chinese
-
Abstract:
【Objective】 To investigate the significance of granulocyte macrophage colony-stimulating factor (GM-CSF), nerve growth factor (NGF) and interleukin-17 (IL-17) in the prostate tissue of rats with experimental autoimmune prostatitis(EAP). 【Methods】 EAP rat models were established and divided into control group, EAP group, anti-GM-CSF group (blocking control group) and anti-GM-CSFEAP group (blocking EAP group). Pain behaviors were tested. The pathological changes were observed with HE staining. The mRNA and protein expressions of GM-CSF, NGF and IL-17 were detected with RT-PCR and Western blot. 【Results】 Pain test showed the anti-GM-CSF group had less chronic pelvic pain than the EAP group. HE staining showed the anti-GM-CSF group had less tissue inflammatory response. The EAP inflammation score was higher in the control group than in the anti-GM-CSF group. Immunohistochemistry showed GM-CSF was positive in the EAP group (mainly in the nucleus). RT-PCR and Western blot results showed the mRNA and protein expressions of IL-17 and NGF significantly decreased 50 days after EAP in the anti-GM-CSF group. 【Conclusion】 Increased expressions of GM-CSF, NGF and IL-17 in prostate tissue of EAP rats may be important inflammatory mediators of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS);decreased expressions of NGF and IL-17 after resistance against GM-CSF indicate that GM-CSF may be a potential therapeutic target for CP/CPPS.
